AMED250117C70000
- 0.00
- 0.000.00%
Amedisys Newsroom
Do Options Traders Know Something About Amedisys (AMED) Stock We Don't?
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neurocrine (NBIX) and Amedisys (AMED)
10 Health Care Stocks Whale Activity In Today's Session
Amedisys Falls as Divestiture Buyer in Sale to UnitedHealth Has Legal Judgement Against It
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape
UnitedHealth's $33B Deal With Hospice Provider Blocked By DOJThe Deal Values Amedisys at $101 a Share
Express News | UnitedHealth Says 'Will Vigorously Defend Against The DOJ's Overreaching'
UnitedHealth's Effort to Buy Another Home Health Provider at Risk Amid DOJ Lawsuit
Express News | Optum - Will Vigorously Defend Against Doj’s Legal Action Aimed at Blocking Proposed Deal of Optum and Amedisys
Sector Update: Health Care Stocks Slipping Tuesday Afternoon
News Highlights: Top Company News of the Day - Tuesday at 1 PM ET
Top Midday Decliners
Express News | Amedisys Shares Down 1.6%
Top Midday Stories: Tyson Foods Reports Q4 EPS, Revenue Beats; DOJ Reportedly Moving to Block UnitedHealth's Amedisys Acquisition
Market Chatter: DOJ Moving to Block UnitedHealth's $3.3 Billion Acquisition of Amedisys
Express News | US Justice Department Preps Suit Over UnitedHealth-Amedisys Deal - Bloomberg News
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls